<var id="ndj7z"><video id="ndj7z"><thead id="ndj7z"></thead></video></var>
<menuitem id="ndj7z"><strike id="ndj7z"><thead id="ndj7z"></thead></strike></menuitem>
<var id="ndj7z"></var>
<var id="ndj7z"><video id="ndj7z"></video></var>
<cite id="ndj7z"></cite>
<var id="ndj7z"></var>
<var id="ndj7z"></var>
<cite id="ndj7z"><strike id="ndj7z"><menuitem id="ndj7z"></menuitem></strike></cite> <cite id="ndj7z"><video id="ndj7z"></video></cite>
<cite id="ndj7z"><video id="ndj7z"><menuitem id="ndj7z"></menuitem></video></cite>
<var id="ndj7z"><strike id="ndj7z"></strike></var><var id="ndj7z"></var>
您好,歡迎訪問中山大學腫瘤防治中心官方網站!
內部網 職工郵箱 圖書館 OA系統 醫生門戶 English
院士風采 首席專家 臨床專家 科研學者 客座教授 人才名錄 護理專家
首頁
  • 李宇紅

    職務:內科二區區長
    職稱:教授、主任醫師、博士生導師
    專長:擅長消化道腫瘤(食管癌、胃癌、腸癌、胰腺癌、膽管癌、胃腸胰神經內分泌腫瘤等)和鼻咽癌的內科治療(化學治療、靶向治療)。
    1.姓名:李宇紅 
    2.職稱:教授、主任醫師、博士生導師
    3.專長:擅長消化道腫瘤(腸癌、胃癌、食管癌、胰腺癌、膽管癌、胃腸胰神經內分泌腫瘤等)的化療和分子靶向藥物治療
    4.出診時間:周二上午 

    5.學術兼職:
    廣東抗癌協會分子靶向與個體化治療專業委員會副主任委員(侯任主委員)
    廣東省醫學會消化道腫瘤分會副主任委員
    廣東省抗癌協會食管癌專業委員會副主任委員
    廣東省抗癌協會大腸癌專業委員會常務委
    中國抗癌協會分子靶向專業委員會常委
    中國大腸癌專業委員會化療學組委員
    中國抗癌協會胰腺癌專業委員會神經內分泌腫瘤學組委員

    6.個人簡介: 
      從事腫瘤內科臨床工作20余年,尤其在消化道腫瘤(腸癌、胃癌、食管癌、胰腺癌、膽管癌、胃腸胰神經內分泌腫瘤等)治療方面有較豐富的經驗。近年來,主要專注于消化道腫瘤的臨床和轉化研究工作。2007年和2009年分別赴法國Paul Brouss醫院和美國Mayo Clinic短期進修消化道腫瘤治療。主持和參加國家自然科學基金、廣東省自然科學基金、廣州市協同創新重大專項等多項基金項目。公開發表論文100余篇,其中以第一作者或通訊作者在《Clinical Cancer Research》, 《Annals of Oncology》, 《Cancer》等雜志發表SCI論文近30篇。為“結直腸癌的個體化治療研究和應用”項目的重要完成人之一,該項目榮獲2016年國家科技進步二等獎,2015年中華科技獎一等獎、2015年廣東省科技進步一等獎。
    1.姓名:李宇紅
    2.職稱:教授、主任醫師、博士生導師
    3.專長:擅長消化道腫瘤(腸癌、胃癌、食管癌、胰腺癌、膽管癌、胃腸胰神經內分泌腫瘤等)的化療和分子靶向藥物治療
    4.出診時間:周二上午 

    5.學術兼職:
    廣東抗癌協會分子靶向與個體化治療專業委員會副主任委員(侯任主委員)
    廣東省醫學會消化道腫瘤分會副主任委員
    廣東省抗癌協會食管癌專業委員會副主任委員
    廣東省抗癌協會大腸癌專業委員會常務委
    中國抗癌協會分子靶向專業委員會常委
    中國大腸癌專業委員會化療學組委員
    中國抗癌協會胰腺癌專業委員會神經內分泌腫瘤學組委員

    6.個人簡介: 
      從事腫瘤內科臨床工作20余年,尤其在消化道腫瘤(腸癌、胃癌、食管癌、胰腺癌、膽管癌、胃腸胰神經內分泌腫瘤等)治療方面有較豐富的經驗。近年來,主要專注于消化道腫瘤的臨床和轉化研究工作。2007年和2009年分別赴法國Paul Brouss醫院和美國Mayo Clinic短期進修消化道腫瘤治療。主持和參加國家自然科學基金、廣東省自然科學基金、廣州市協同創新重大專項等多項基金項目。公開發表論文100余篇,其中以第一作者或通訊作者在《Clinical Cancer Research》, 《Annals of Oncology》, 《Cancer》等雜志發表SCI論文近30篇。為“結直腸癌的個體化治療研究和應用”項目的重要完成人之一,該項目榮獲2016年國家科技進步二等獎,2015年中華科技獎一等獎、2015年廣東省科技進步一等獎。

    7.代表性文章:
    1. Li YH, Wang F, et al. EGFR FISH Pattern of Chromosome 7 Disomy Predicts Resistance to Cetuximab in KRAS Wild-type Metastatic Colorectal Cancer patients. Clin Cancer Res.2011: 15; 17(2):382.
    2. Luo HY, Li YH, (contribute equally), et al. Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety. Ann of Oncol.2016: 27: 1074.
    3. Wang FH, Li YH (Corresponds), et al. Efficacy and safety of recombinant human  lymphotoxin-alpha derivative with cisplatin and fluorouracil in patients with metastatic esophageal squamous cell carcinoma: A randomized, multicenter, open-label, controlled, phase 2b trial. Cancer. 2017, 123: 3986.
    4. An X, Li YH (Corresponds), et al.. MET amplification is not rare and predicts unfavorable clinical outcomes in patients with recurrent/metastatic gastric cancer after chemotherapy. Cancer. 2014 Mar 1; 120(5):675.
    5. An X, Li YH (Corresponds), et al. Plasma Epstein-Barr virus DNA level strongly predicts survival in metastatic/recurrent nasopharyngeal carcinoma treated with palliative chemotherapy. Cancer. 2011; 15; 117(16):3750.
    6. Li YH, He YF, et al. Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma. Cancer. 2006, 15; 106(6):1320
    7. Wang Y, Li YH (Corresponds), et al. The Immunoscore system predicts pro gnosis after liver metastasectomy in colorectal cancer liver metastases. Cancer Immunol Immunother.  2017 Online. 
    8. Wang Y, Li YH (Corresponds), et al.. Pathologic response after preoperative therapy predicts prognosis of Chinese colorectal cancer patients with liver metastases .Chin J Cancer. 2017, 36: 78.
    9. Wang Y, Li YH (Corresponds), et al. The Role of Adjuvant Chemotherapy for Colorectal Liver Metastasectomy after Pre-Operative Chemotherapy: Is the Treatment Worthwhile? J Cancer .2017:8: 1179.
    10. Wang Y, Li YH (Corresponds), et al.. Predictive value of chemotherapy-related high-density lipoprotein cholesterol (HDL) elevation in patients with colorectal cancer receiving adjuvant chemotherapy: an exploratory analysis of 851 cases. Oncotarget.  2017:7: 57290.
    11. Zhang F, Li YH (Corresponds), et al. Fibrinogen promotes malignant biological tumor behavior involving epithelial-mesenchymal transition via the p-AKT/p-mTOR pathway in esophageal squamous cell carcinoma. J Cancer s Res Clin  Oncol. 2017:143(12):2413.
    12. Zhang F, Li YH (Corresponds), et al. Efficacy and safety of cisplatin-based versus nedaplatin-based regimens for the treatment of metastatic/recurrent and advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis.  Dis Esophagus.2017; 30: 1.
    13. Cong Li, Li YH (Corresponds), et al. Phase I trial of hepatic arterial infusion (HAI) of floxuridine with modified oxaliplatin, 5‑fluorouracil and leucovorin (m‑FOLFOX6) in Chinese patients with unresectable liver metastases from colorectal cancer. Cancer Chemother Pharmacol.2014: 74:1079.
    14. Zhang L, Li YH (Corresponds), et al. MGMT in colorectal cancer: a promising component of personalized treatment. Tumour Biol. 2016 Mar 22.
    15. Li YH, Qiu MZ, et al. S-1 plus cisplatin versus fluorouracil plus cisplatin in advanced gastric or gastro-esophageal junction adenocarcinoma patients: a pilot study. Oncotarget. 2015; (33):35107.  
    16. Wang Y, Li YH (Corresponds), et al. Effect of Raf kinase inhibitor protein expression on malignant biological behavior and progression of colorectal cancer. Oncol Rep. 2015; 34(4):2106.  
    17. Jiang YX, Li YH (Corresponds), et al. Inhibition of MiR-155 suppresses cell migration in nasopharyngeal carcinoma through targeting ZDHHC2. Int J Clin Exp Med. 2015; 8(6):8472.
    18. An X, Li YH (Corresponds), et al. Serum HER 2 extracellular domain level is correlated with tissue HER 2 status in metastatic gastric or gastro-oesophageal junction adenocarcinoma. PLoS One. 2013 May 14; 8(5):e63458. 
    19. Chen C, Li YH (Corresponds), et al. Polymorphisms in ERCC1 C8092A predict progression-free survival in metastatic/recurrent nasopharyngeal carcinoma treated with cisplatin-based chemotherapy. Cancer Chemother Pharmacol. 2013 Aug; 72(2):315.
    20. Chen C, Li YH (Corresponds), et al.Triplet combination with paclitaxel, cisplatin and 5-FU is effective in metastatic and/or recurrent nasopharyngeal carcinoma. Cancer Chemotherapy Pharmacol. 2013 Feb; 71(2):371.
    21. Chen C, Li YH (Corresponds), et al. Salvage gemcitabine-vinorelbine chemotherapy in patients with metastatic nasopharyngeal carcinoma pretreated with platinum- based chemotherapy. Oral Oncol. 2012 Nov; 48(11):1146. 
    22. An X, Li YH (Corresponds), et al. Elevated neutrophil to lymphocyte ratio predicts poor prognosis in nasopharyngeal carcinoma. Tumor Biol. 2011; 32(2):317.
    23. Wang FH, Li YH (Corresponds), et al. Phase II study of biweekly paclitaxel plus infusional 5-fluorouracil and leucovorin as first-line chemotherapy in patients with advanced gastric cancer. Am J Clin Oncol. 2011; 34(4):401.
    24. Li YH, Luo HY, et al. Phase II study of capecitabine plus oxaliplatin(XELOX) as first-line treatment and followed by maintenance of capecitabine in patients with metastatic colorectal cancer. J Cancer Res Clin Oncol. 2010; 136(4):503.
    25. An X, Li YH (Corresponds), et al. Carcinoembryonic antigen surge in metastatic colorectal cancer patients responding to irinotecan combination chemotherapy. Biomarkers. 2010; 15(3):243. 
    26. Li YH, Hu CF, et al. Elevated Expressions of Survivin and VEGF Protein are Strong Independent Predictors of Survival in Advanced Nasopharyngeal Carcinoma. J Transl Med. 2008; 3; 6(1):1.
    27. Li YH, Wang FH, et al. Phase II study of capecitabine and cisplatin combination as first-line chemotherapy in Chinese patients with metastatic nasopharyngeal carcinoma. Cancer Chemother Pharmacol. 2008; 62(3):539. 
    28. He YF, Li YH (Corresponds) et al. The effectiveness of lamivudine in preventing hepatitis B viral reactivation in rituximab-containing regimen for lymphoma. Ann Hematol. 2008; 87(6):481.


    更新日期:2018年1月31日
訪客通道
員工通道
關注腫瘤醫院
留言建議 ×
沙巴体育下载